Plasmin substrate Tosyl-GPKpNA, chromogenic


N-(p-Tosyl)-Gly-Pro-Lys-pNA acetate

Order
Quantity
Price
Status
25 mg 315 € available


Documents
Art. No. T004
Synonym N-(p-Tosyl)-Gly-Pro-Lys 4-nitroanilide acetate salt;
N-Tosylglycyl-L-prolyl-L-lysine 4-nitroanilide acetate salt
Molecular Formula C28H38N6O9S (free base: C26H34N6O7S)
Molecular Weight 634.70 (free base: 574.65)
Purity by HPLC >90 % (214 nm)
Appearance Pale yellow solid
Solubility 6 mg/ml in aqueous buffers.
Aqueous stock solutions can be stored at -20°C for at least 6 months. To avoid too many freeze-thaw cycles, we strongly recommend storage of aliquots.
Application Chromogenic substrate for plasmin and other coagulation proteases
Storage Store at -20°C, desiccate
Reference(s) Lottenberg, R. et al. Meth. Enzymol. 1981, 80-C, 341.
Note INTENDED FOR RESEARCH USE ONLY, NOT FOR USE IN HUMAN,
THERAPEUTIC OR DIAGNOSTIC APPLICATIONS.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • 19th International Celiac Disease Symposium

    14.10.2021 - 17.10.2021
    Sorrento, Italy

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA